

## Addressee(s)

Registrant(s) of JS\_223-829-1 as listed in Appendix 3 of this decision

## **Date of submission of the dossier subject to this decision** 09/03/2022

#### Registered substance subject to this decision ("the Substance")

Substance name: 2,2'-oxybis[5,5-dimethyl-1,3,2-dioxaphosphorinane] 2,2'-disulphide EC/List number: 223-829-1

**Decision number:** Please refer to the REACH-IT message which delivered this communication (in format TPE-D-XXXXXXXXXXXXXXXXX/F)

## DECISION ON TESTING PROPOSAL(S)

Under Article 40 of Regulation (EC) No 1907/2006 (REACH), you must submit the information listed below by **2** *February* **2026**.

Requested information must be generated using the Substance unless otherwise specified.

#### Information required from all the Registrants subject to Annex IX of REACH

1. Sub-chronic toxicity study (90-day) (Annex IX, Section 8.6.2.; test method: OECD TG 408) by oral route, in rats

The reasons for the decision(s) are explained in Appendix 1.

#### Information required depends on your tonnage band

You must provide the information listed above for all REACH Annexes applicable to you in accordance with Articles 10(a) and 12(1) of REACH. The addressee(s) of the decision and their corresponding information requirements based on registered tonnage band are listed in Appendix 3.

You are only required to share the costs of information that you must submit to fulfil your information requirements.

#### How to comply with your information requirements

To comply with your information requirements, you must submit the information requested by this decision in an updated registration dossier by the deadline indicated above. You must also **update the chemical safety report**, where relevant, including any changes to classification and labelling, based on the newly generated information.

You must follow the general requirements for testing and reporting new tests under REACH, see Appendix 4.

## Appeal

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to



http://echa.europa.eu/regulations/appeals for further information.

#### Failure to comply

If you do not comply with the information required by this decision by the deadline indicated above, ECHA will notify the enforcement authorities of your Member State.

Authorised<sup>1</sup> under the authority of Mike Rasenberg, Director of Hazard Assessment

Appendix 1: Reasons for the decision

Appendix 2: Procedure

Appendix 3: Addressees of the decision and their individual information requirements

Appendix 4: Conducting and reporting new tests under REACH

<sup>&</sup>lt;sup>1</sup> As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.



## Appendix 1: Reasons for the decision

## Contents

	Reasons for the decision(s) related to the information under Annex IX of REACH4					
	Sub-chronic toxicity study (90-days)					
Refe	erences	s6				



## Reasons for the decision(s) related to the information under Annex IX of REACH

## **1.** Sub-chronic toxicity study (90-days)

1 A sub-chronic toxicity study (90 day) is an information requirement under Annex IX, Section 8.6.2.

#### 1.1. Information provided to fulfil the information requirement

- 2 You have submitted a testing proposal for a Sub-chronic toxicity study (90 day) according to OECD TG 408 with the Substance.
- 3 ECHA requested your considerations for alternative methods to fulfil the information requirement for Repeated dose toxicity. You provided your considerations concluding that there were no alternative methods which could be used to adapt the information requirement(s) for which testing is proposed. ECHA has taken these considerations into account.
- 4 ECHA received third party information concerning the testing proposal during the thirdparty consultation.
- 5 A third party has indicated "a combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422) with the Registered Substance reports a NOAEL of 1000 mg/kg bw/d. Published analyses of toxicological data in REACH Registration Dossiers (Taylor et al, 2014; Taylor & Andrew, 2017) demonstrate that, for low toxicity substances reporting a NOAEL of 1000 mg/kg bw/d, there is no added value for the human risk assessment if a 90-day study is performed. As this substance appears to meet the definition of a 'low toxicity substance', a 90-day study is not scientifically justified and not in the interests of animal welfare.".
- 6 ECHA understands that the third-party comments refer to the adaptation possibility under Annex IX, Section 8.6.2., column 2, fourth indent. This adaptation specifies that a subchronic toxicity study (90-day) does not need to be conducted if "the substance is unreactive, insoluble and not inhalable <u>and</u> there is no evidence of absorption <u>and</u> no evidence of toxicity in a 28-day study, particularly if such a pattern is coupled with limited human exposure". ECHA notes that all criteria need to be met.
- 7 ECHA observes that the third-party comments addressed only the criterion concerning "no evidence of toxicity". The third party did not submit information regarding the other cumulative criteria under Annex IX, Section 8.6.2., column 2, fourth indent.
- 8 Therefore, the information submitted by the third party does not demonstrate that the cumulative criteria listed in Annex IX, section 8.6.2., column 2, fourth indent are met.
- 9 ECHA notes that it is your responsibility to consider and justify in the registration dossier any adaptation of the information requirements in accordance with Annex IX, Section 8.6.2., column 2, fourth indent.
- 10 On this basis, ECHA agrees that a 90-day study is necessary.

#### 1.2. Specification of the study design

11 You proposed testing in the rat. ECHA agrees with your proposal because the rat is the preferred species according to the OECD TG 408. Therefore, the study must be conducted in the rat.



12 You proposed testing by the oral route. ECHA agrees with your proposal because this route of administration is appropriate to investigate systemic toxicity; Guidance on IRs and CSA, Section R.7.5.4.3.2.

## 1.3. Outcome

13 Your testing proposal is accepted under Article 40(3)(a) and you are requested to conduct the test with the Substance, as specified above.



## References

The following documents may have been cited in the decision.

# *Guidance on information requirements and chemical safety assessment (Guidance on IRs & CSA)*

- Chapter R.4 Evaluation of available information; ECHA (2011).
- Chapter R.6 QSARs, read-across and grouping; ECHA (2008).
- Appendix to Chapter R.6 for nanoforms; ECHA (2019). Chapter R.7a Endpoint specific guidance, Sections R.7.1 – R.7.7; ECHA (2017). Appendix to Chapter R.7a for nanomaterials; ECHA (2017).
- Chapter R.7b Endpoint specific guidance, Sections R.7.8 R.7.9; ECHA (2017). Appendix to Chapter R.7b for nanomaterials; ECHA (2017).
- Chapter R.7c Endpoint specific guidance, Sections R.7.10 R.7.13; ECHA (2017). Appendix to Chapter R.7a for nanomaterials; ECHA (2017). Appendix R.7.13-2 Environmental risk assessment for metals and metal compounds; ECHA (2008).
- Chapter R.11 PBT/vPvB assessment; ECHA (2017).
- Chapter R.16 Environmental exposure assessment; ECHA (2016).

**Guidance on data-sharing**; ECHA (2017). **Guidance for monomers and polymers**; ECHA (2012). **Guidance on intermediates;** ECHA (2010).

All guidance documents are available online: <u>https://echa.europa.eu/guidance-documents/guidance-on-reach</u>

## Read-across assessment framework (RAAF)

RAAF, 2017Read-across assessment framework (RAAF); ECHA (2017)RAAF UVCB, 2017Read-across assessment framework (RAAF) – considerations on<br/>multi- constituent substances and UVCBs); ECHA (2017).

The RAAF and related documents are available online: <u>https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across</u>

## **OECD Guidance documents (OECD GDs)**

OECD GD 23	Guidance document on aquatic toxicity testing of difficult
	substances and mixtures; No. 23 in the OECD series on testing and assessment, OECD (2019).
OECD GD 29	Guidance document on transformation/dissolution of metals and
	metal compounds in aqueous media; No. 29 in the OECD series on
	testing and assessment, OECD (2002).
OECD GD 150	Revised guidance document 150 on standardised test guidelines for
	evaluating chemicals for endocrine disruption; No. 150 in the OECD
	series on testing and assessment, OECD (2018).
OECD GD 151	Guidance document supporting OECD test guideline 443 on the
	extended one-generation reproductive toxicity test; No. 151 in the
	OECD series on testing and assessment, OECD (2013).



## **Appendix 2: Procedure**

ECHA started the testing proposal evaluation in accordance with Article 40(1) on 20 April 2022.

ECHA held a third-party consultation for the testing proposal(s) from 16 June 2022 until 1 August 2022. ECHA received information from third parties (see corresponding Appendix/Appendices

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the commenting period.

The deadline of the decision is set based on standard practice for carrying out OECD TG tests. It has been exceptionally extended by 12 months from the standard deadline granted by ECHA to take into account currently longer lead times in contract research organisations.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.



# Appendix 3: Addressee(s) of this decision and their corresponding information requirements

In accordance with Articles 10(a) and 12(1) of REACH, the information requirements for individual registrations are defined as follows:

- the information specified in Annex VII to REACH, for registration at 1-10 tonnes per year (tpa), or as a transported isolated intermediate in quantity above 1000 tpa;
- the information specified in Annexes VII and VIII to REACH, for registration at 10-100 tpa;
- the information specified in Annexes VII, VIII and IX to REACH, for registration at 100-1000 tpa;
- the information specified in Annexes VII to X to REACH, for registration at more than 1000 tpa.

Registrant Name	Registration number	Highest REACH Annex applicable to you

Where applicable, the name of a third-party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.



## Appendix 4: Conducting and reporting new tests for REACH purposes

# 1. Requirements when conducting and reporting new tests for REACH purposes

#### 1.1. Test methods, GLP requirements and reporting

- (1) Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.
- (2) Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.
- (3) Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries<sup>2</sup>.
- (4) Under the introductory part of Annexes VII/VIII/IX/X to REACH, where a test method offers flexibility in the study design, for example in relation to the choice of dose levels or concentrations, the chosen study design must ensure that the data generated are adequate for hazard identification and risk assessment.

#### 1.2. Test material

Before generating new data, you must agree within the joint submission on the chemical composition of the material to be tested (Test Material) which must be relevant for all the registrants of the Substance.

(1) Selection of the Test material(s)

The Test Material used to generate the new data must be selected taking into account the following:

- the variation in compositions reported by all members of the joint submission,
- the boundary composition(s) of the Substance,
- the impact of each constituent/ impurity on the test results for the endpoint to be assessed. For example, if a constituent/ impurity of the Substance is known to have an impact on (eco)toxicity, the selected Test Material must contain that constituent/ impurity.
- (2) Information on the Test Material needed in the updated dossier
  - You must report the composition of the Test Material selected for each study, under the "Test material information" section, for each respective endpoint study record in IUCLID.
  - The reported composition must include all constituents of each Test Material and their concentration values and other parameters relevant for the property to be tested.

This information is needed to assess whether the Test Material is relevant for the Substance and whether it is suitable for use by all members of the joint submission.

Technical instructions on how to report the above is available in the manual on How to prepare registration and PPORD dossiers<sup>3</sup>.

<sup>&</sup>lt;sup>2</sup> <u>https://echa.europa.eu/practical-guides</u>

<sup>&</sup>lt;sup>3</sup> <u>https://echa.europa.eu/manuals</u>